IDEAYA Biosciences Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 124

Employees

  • Stock Symbol
  • IDYA

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $23.00
  • (As of Friday Closing)

IDEAYA Biosciences General Information

Description

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 7000 Shoreline Court
  • Suite 350
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 7000 Shoreline Court
  • Suite 350
  • South San Francisco, CA 94080
  • United States
+1 (650)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

IDEAYA Biosciences Stock Performance

As of 07-Feb-2025, IDEAYA Biosciences’s stock price is $23.00. Its current market cap is $1.99B with 86.4M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$23.00 $23.96 $22.10 - $47.73 $1.99B 86.4M 919K -$2.33

IDEAYA Biosciences Financials Summary

As of 30-Sep-2024, IDEAYA Biosciences has a trailing 12-month revenue of $3.92M.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 1,976,585 1,826,814 491,902 651,108
Revenue 3,922 23,385 50,931 27,941
EBITDA (220,539) (131,929) (58,987) (47,236)
Net Income (178,120) (112,961) (58,655) (49,762)
Total Assets 1,239,873 649,316 387,969 381,347
Total Debt 18,796 2,872 3,482 5,181
Public Fundamental Data provided by Morningstar, Inc. disclaimer

IDEAYA Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore IDEAYA Biosciences‘s full profile, request access.

Request a free trial

IDEAYA Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore IDEAYA Biosciences‘s full profile, request access.

Request a free trial

IDEAYA Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of t
Drug Discovery
South San Francisco, CA
124 As of 2023

Farmington, CT
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

IDEAYA Biosciences Competitors (66)

One of IDEAYA Biosciences’s 66 competitors is CaroGen, a Venture Capital-Backed company based in Farmington, CT.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CaroGen Venture Capital-Backed Farmington, CT
Vedanta Biosciences Venture Capital-Backed Cambridge, MA
858 Therapeutics Venture Capital-Backed San Diego, CA
Sorrento Therapeutics Formerly VC-backed San Diego, CA
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 66 competitors. Get the full list »

IDEAYA Biosciences Patents

IDEAYA Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240327399-A1 Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof Pending 09-Dec-2022
AU-2023279251-A1 Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof Pending 01-Jun-2022
US-20230303556-A1 Piperazine substituted indazole compounds as inhibitors of parg Pending 23-Mar-2022
AU-2023239344-A1 Piperazine substituted indazole compounds as inhibitors of parg Pending 23-Mar-2022
EP-4496795-A1 Piperazine substituted indazole compounds as inhibitors of parg Pending 23-Mar-2022 C07D417/14
To view IDEAYA Biosciences’s complete patent history, request access »

IDEAYA Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

IDEAYA Biosciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore IDEAYA Biosciences‘s full profile, request access.

Request a free trial

IDEAYA Biosciences Investments (1)

IDEAYA Biosciences’s most recent deal was a Corporate Asset Purchase with Novartis (IDE196 Global Rights in Basel, Switzerland) for . The deal was made on 01-Sep-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Novartis (IDE196 Global Rights in Basel, Switzerland) 01-Sep-2018 Corporate Asset Purchase Buildings and Property
To view IDEAYA Biosciences’s complete investments history, request access »

IDEAYA Biosciences ESG

Risk Overview

Risk Rating

Updated July, 29, 2023

33.66 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,120

Rank

Percentile

Pharmaceuticals

Industry

of 853

Rank

Percentile

Pharmaceuticals

Subindustry

of 425

Rank

Percentile

To view IDEAYA Biosciences’s complete esg history, request access »

IDEAYA Biosciences FAQs

  • When was IDEAYA Biosciences founded?

    IDEAYA Biosciences was founded in 2015.

  • Where is IDEAYA Biosciences headquartered?

    IDEAYA Biosciences is headquartered in South San Francisco, CA.

  • What is the size of IDEAYA Biosciences?

    IDEAYA Biosciences has 124 total employees.

  • What industry is IDEAYA Biosciences in?

    IDEAYA Biosciences’s primary industry is Drug Discovery.

  • Is IDEAYA Biosciences a private or public company?

    IDEAYA Biosciences is a Public company.

  • What is IDEAYA Biosciences’s stock symbol?

    The ticker symbol for IDEAYA Biosciences is IDYA.

  • What is the current stock price of IDEAYA Biosciences?

    As of 07-Feb-2025 the stock price of IDEAYA Biosciences is $23.00.

  • What is the current market cap of IDEAYA Biosciences?

    The current market capitalization of IDEAYA Biosciences is $1.99B.

  • What is IDEAYA Biosciences’s current revenue?

    The trailing twelve month revenue for IDEAYA Biosciences is $3.92M.

  • Who are IDEAYA Biosciences’s competitors?

    CaroGen, Vedanta Biosciences, 858 Therapeutics, Sorrento Therapeutics, and CytomX Therapeutics are some of the 66 competitors of IDEAYA Biosciences.

  • What is IDEAYA Biosciences’s annual earnings per share (EPS)?

    IDEAYA Biosciences’s EPS for 12 months was -$2.33.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »